Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 17.80K | 33.20K | -1.22M | 123.40K | 754.30K |
| Gross Profit | -17.80K | -33.20K | 1.22M | -123.40K | -754.30K |
| SG&A Expenses | 1.39M | 2.49M | 1.02M | 1.15M | 986.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.41M | 2.53M | 973.00K | 1.27M | 1.74M |
| Operating Income | -1.41M | -2.53M | -973.00K | -1.27M | -1.74M |
| Income Before Tax | -1.69M | -2.65M | -850.30K | -1.80M | -1.48M |
| Income Tax Expenses | -- | 0.00 | 5.50K | -2.20K | -1.20K |
| Earnings from Continuing Operations | -1.69M | -2.65M | -855.80K | -1.79M | -1.48M |
| Earnings from Discontinued Operations | -- | -- | 0.00 | -- | -100.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.69M | -2.65M | -855.80K | -1.79M | -1.58M |
| EBIT | -1.41M | -2.53M | -973.00K | -1.27M | -1.74M |
| EBITDA | -- | -- | -971.90K | -1.27M | -1.74M |
| EPS Basic | -1.00 | -1.82 | -1.09 | -4.70 | -10.37 |
| Normalized Basic EPS | -0.50 | -1.05 | -0.34 | -3.41 | -6.16 |
| EPS Diluted | -1.00 | -1.82 | -1.09 | -4.70 | -10.37 |
| Normalized Diluted EPS | -0.50 | -1.05 | -0.34 | -3.41 | -6.16 |
| Average Basic Shares Outstanding | 1.68M | 1.46M | 785.70K | 387.90K | 152.10K |
| Average Diluted Shares Outstanding | 1.68M | 1.46M | 785.70K | 387.90K | 152.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |